Medizinische Universität Graz - Research portal

Logo MUG Resarch Portal

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Jensen, PEH; Warnke, C; Ingenhoven, K; Piccoli, L; Gasis, M; Hermanrud, C; Fernandez-Rodriguez, BM; Ryner, M; Kramer, D; Link, J; Ramanujam, R; Auer, M; Buck, D; Grummel, V; Bertotti, E; Fissolo, N; Oliver-Martos, B; Nytrova, P; Khalil, M; Guger, M; Rathmaier, S; Sievers-Stober, C; Lindberg, RLP; Hässler, S; Bachelet, D; Aktas, O; Donnellan, N; Lawton, A; Hemmer, B; Havrdova, EK; Kieseier, B; Hartung, HP; Comabella, M; Montalban, X; Derfuss, T; Sellebjerg, F; Dönnes, P; Pallardy, M; Spindeldreher, S; Broët, P; Deisenhammer, F; Fogdell-Hahn, A; Sorensen, PS; ABIRISK Consortium.
Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study.
J Neuroimmunol. 2019; 326:19-27 Doi: 10.1016/j.jneuroim.2018.11.002
Web of Science PubMed FullText FullText_MUG


Co-authors Med Uni Graz
Khalil Michael

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Two validated assays, a bridging ELISA and a luciferase-based bioassay, were compared for detection of anti-drug antibodies (ADA) against interferon-beta (IFN-β) in patients with multiple sclerosis. Serum samples were tested from patients enrolled in a prospective study of 18 months. In contrast to the ELISA, when IFN-β-specific rabbit polyclonal and human monoclonal antibodies were tested, the bioassay was the more sensitive to detect IFN-β ADA in patients' sera. For clinical samples, selection of method of ELISA should be evaluated prior to the use of a multi-tiered approach. A titer threshold value is reported that may be used as a predictor for persistently positive neutralizing ADA. Copyright © 2018 Elsevier B.V. All rights reserved.

Find related publications in this database (Keywords)
Multiple sclerosis
Luciferase-based bioassay
Bridging ELISA
Anti-drug antibodies
Neutralizing antibodies
© Med Uni GrazImprint